Best in Class Anti-Infectives
June 2, 2008
Trius Appoints Paul Truex
to Board of Directors
March 24, 2008
Trius Raises $30 Million in Series B Financing
January 7, 2008
Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
September 17, 2007
Trius Presents Study Results of Best-in-Class Antibiotics
in 11 Posters at ICAAC